title: A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia.
abstract: Schizophrenia is characterized by reality distortion, psychomotor poverty and cognitive disturbances. These characteristics contribute to a lesser social functioning and lower quality of life in patients with schizophrenia. It has been suggested that modafinil and its isomer armodafinil as an add-on strategy to antipsychotic treatment in patients with schizophrenia may improve cognitive functioning, attenuate fatigue, inactiveness and other negative functions as well as weight gain. In this paper we review the literature relevant to the question of whether modafinil and armodafinil are beneficial as add-on therapy in antipsychotic-treated patients with schizophrenia. A total of 15 articles were included in this review; of the 15 articles, 10 were randomized controlled trials (RCTs). Evidence for the use of modafinil or armodafinil as add-on therapy to antipsychotic drugs to alleviate fatigue, sleepiness and inactivity is inconclusive. One cohort study and one out of two single-dose crossover RCTs in which modafinil addition was studied could demonstrate a positive effect. All five RCTs of modafinil (three RCTs) and armodafinil (two RCTs) addition with a longer study duration could not demonstrate a positive effect. With respect to cognitive disturbances, animal models of cognitive deficits show clear improvements with modafinil. In RCTs with a treatment duration of 4 weeks or more, however, no positive effect could be demonstrated on cognitive functioning with modafinil and armodafinil addition. Yet, four single-dose crossover RCTs of modafinil addition show significant positive effects on executive functioning, verbal memory span, visual memory, working memory, spatial planning, slowing in latency, impulse control and recognition of faces expressing sadness and sadness misattribution in the context of disgust recognition. The addition of modafinil or armodafinil to an antipsychotic regime, despite theoretical and preclinical considerations, has not been proved to enhance cognitive function, attenuate fatigue, enhance activity, improve negative symptoms and reduce weight in patients with schizophrenia.
authors: GGZ Drenthe, PO Box 30007, 9400 RA Assen, Netherlands.
authors: Laura Christina
authors: LC
authors: Wittkampf
authors: Johannes
authors: J
authors: Arends
authors: Leo
authors: L
authors: Timmerman
authors: Marike
authors: M
authors: Lancel
keywords: armodafinil; cognitive disturbances; fatigue; inactiveness; modafinil; schizophrenia
references: Schizophr Res. 2005 Jan 1;72(2-3):225-34
references: 15560967
references: J Clin Psychiatry. 2007 Apr;68(4):604-10
references: 17474817
references: Neuropsychopharmacology. 2008 Jun;33(7):1477-502
references: 17712350
references: Am J Psychiatry. 2002 Jul;159(7):1243-4
references: 12091210
references: Neuropsychopharmacology. 2011 Jun;36(7):1385-96
references: 21412225
references: CNS Drugs. 2009 Oct;23(10):837-55
references: 19739694
references: Am J Psychiatry. 1993 Dec;150(12):1900-1
references: 8238656
references: Psychopharmacology (Berl). 2009 Jan;202(1-3):287-93
references: 18392753
references: J Neurosci Methods. 2009 Dec 15;185(1):66-9
references: 19761795
references: Schizophr Bull. 2012 May;38(3):457-74
references: 20810469
references: Br J Psychiatry. 2006 Nov;189:461-2
references: 17077439
references: Am J Psychiatry. 2006 Dec;163(12):2184-6
references: 17151173
references: Neuron. 2006 Oct 5;52(1):139-53
references: 17015232
references: Drug Metab Dispos. 2000 Jun;28(6):664-71
references: 10820139
references: J Pharmacol Exp Ther. 2006 Nov;319(2):561-9
references: 16885432
references: Schizophr Res. 2011 Aug;130(1-3):106-13
references: 21641776
references: J Clin Psychiatry. 2005 Jul;66(7):839-43
references: 16013898
references: Schizophr Bull. 2007 Sep;33(5):1225-37
references: 17204532
references: Clin Ther. 2010 Nov;32(12):2074-87
references: 21118743
references: J Clin Psychiatry. 2009 Dec;70(12):1674-80
references: 19689921
references: Front Psychiatry. 2010 Nov 11;1:146
references: 21423454
references: Behav Brain Res. 2010 Mar 17;208(1):118-23
references: 19914296
references: Br J Psychiatry. 2005 Jul;187:55-61
references: 15994572
references: Schizophr Res. 2011 Aug;130(1-3):53-6
references: 21565464
references: J Clin Psychiatry. 2003 Apr;64(4):485-6
references: 12716260
references: Schizophr Res. 2008 Apr;101(1-3):273-86
references: 18258416
references: Lancet. 2009 Jan 3;373(9657):31-41
references: 19058842
references: Schizophr Bull. 2008 May;34(3):494-506
references: 17932088
references: Psychopharmacology (Berl). 1991;103(1):28-32
references: 1672457
references: Clin Neuropharmacol. 2004 Jan-Feb;27(1):38-43
references: 15090936
references: Biol Psychiatry. 2011 Mar 1;69(5):457-64
references: 21109234
references: Cleve Clin J Med. 2007 Aug;74(8):561-6, 568-71
references: 17708127
references: J Neurosci. 2001 Mar 1;21(5):1787-94
references: 11222668
references: Arch Gen Psychiatry. 2002 Mar;59(3):292-3
references: 11879175
references: J Clin Psychiatry. 2007 May;68(5):705-10
references: 17503979
references: N Engl J Med. 1991 Mar 14;324(11):746-54
references: 1671793
references: Sleep. 2004 Feb 1;27(1):19-25
references: 14998233
references: Ann Clin Psychiatry. 2005 Apr-Jun;17(2):95-7
references: 16075662
references: J Pharmacol Exp Ther. 1995 Mar;272(3):984-90
references: 7891353
references: J Clin Psychiatry. 2004 Feb;65(2):278-9; author reply 279
references: 15003090
references: Neuroreport. 2001 Nov 16;12(16):3533-7
references: 11733706
references: Br J Psychiatry. 2004 Sep;185:196-204
references: 15339823
references: Am J Psychiatry. 2008 Aug;165(8):978-87
references: 18450928
references: Neuropsychopharmacology. 2004 Jul;29(7):1363-73
references: 15085092
references: Neuroreport. 1997 Sep 8;8(13):2883-7
references: 9376524
references: J Clin Psychiatry. 2010 Nov;71(11):1475-81
references: 20816042
references: Neurosci Lett. 2003 Mar 20;339(2):143-6
references: 12614915